| Revenue Growth | Q3 net revenue $16.2M, up 38% year-over-year; FY26 guidance raised to 44-48%. |
|---|---|
| Mgmt Confidence | High conviction in guidance; momentum durable as they close out the year. |
| Demand Visibility | Encouraging start to Q4; deep funnel of 1,800 high-volume US specialists. |
| Margin Trends | Q3 gross margin 78.5%, up from 76.2% prior year; pricing discipline maintained. |
| Op. Leverage | SG&A as percentage of revenue expected to increase in Q4 due investments. |
| Pricing Power | Sustained pricing discipline; new products supporting ASP despite ASC pricing pressure. |
| Vol vs Price | Growth driven by 34% implant volume increase and year-over-year ASP gains. |
| Segment Growth | Core surgeon category derived majority of implant volume growth this quarter. |
| New Clients | Added new customers ahead of plan; 150 surgeon engagement events YTD. |
| Capex & Debt | Cash balance $92.3M; cash flow break-even expected with cash on hand. |
| Regulatory | Favorable CMS final rulings; INSET NEO robotics FDA submission planned H1 2027. |
| Commentary | Focus on 'prospect to contender to core' surgeon progression for predictable growth. |
| New Launches | Launched INSETGO, N22 Humeral Head; INSET 1 and Clutch Guide coming 2027. |
Growth
Q3 revenue grew 38% to $16.2M; implant volume increased 34% to 2,126 units.
Outlook
Raised FY2026 revenue guidance to $68M-$70M, representing 44% to 48% year-over-year growth.
Risks
Management noted pronounced seasonality among tenured surgeons and pricing pressure in ambulatory surgery centers.
The company's earnings call, NYSE: SI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Shoulder Innovations, Inc.: key numbers
- Share price
- $20.45Close, Nov 16
- Market cap
- $428M
- Shares outstanding
- 20.92MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Shoulder Innovations, Inc.
All →Shoulder Innovations Q3 2026 Results: Net Loss of $7.05M, Loss Narrows
Shoulder Innovations, Inc. reported net revenue of $50.07 million for the nine months ended September 30, 2026, a significant increase from $32.90 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $25.58 million for the period as it continues to invest heavily in research and development and selling, general, and administrative expenses.
- Key figure
- Net loss $7.05M
Shoulder Innovations Financial Results
Shoulder Innovations reported Q3 2026 revenue of $16.2 million, a 38% year-over-year increase driven by higher implant system sales and surgeon adoption. The company raised its full-year 2026 revenue guidance to a range of $68 million to $70 million and highlighted the commercial launch of its N-22 humeral head.
“Our third quarter results reflect the consistency of our commercial model, as we added new surgeons ahead of plan, grew volume within our existing customer base, and kept our product roadmap moving.”
Rob Ball, CEO of Shoulder Innovations
“This performance enabled us to again raise our outlook for the full year, and confirmed our conviction regarding our ability to grow market share through a differentiated approach to shoulder surgical care.”
Rob Ball, CEO of Shoulder Innovations
Shoulder Innovations Product Launch
Shoulder Innovations announced the limited user release and commercial launch of InSet Go, its next-generation glenoid implant for anatomic shoulder arthroplasty. The launch follows the successful completion of the first surgical case and aims to improve procedural efficiency while maintaining the company's clinically-proven design for implant stability.